NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Allen Chiang, MD, discusses three subanalyses from the DERBY and OAKS studies of pegcetacoplan for the treatment of geographic atrophy.
“In the latter part of the 18-month to 24-month part of the clinical trial data, we saw that the lesion growth reduced by a greater amount, by 30%, in monthly treated eyes vs. 24% in the every other month treated eyes vs. sham,” Chiang said. “So, that is a concept that is important.”
In addition to reviewing the topline data for pegcetacoplan, the analysis “unpacks